|
TNRC6B expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62481139653892E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
9.99200722162641E-16 |
| Normal-vs-Stage2 |
8.36450000374356E-08 |
| Normal-vs-Stage3 |
3.44169137633799E-14 |
| Normal-vs-Stage4 |
6.88338275267597E-15 |
| Stage1-vs-Stage2 |
5.767600E-01 |
| Stage1-vs-Stage3 |
2.434200E-02 |
| Stage1-vs-Stage4 |
2.243900E-03 |
| Stage2-vs-Stage3 |
3.508000E-02 |
| Stage2-vs-Stage4 |
1.256060E-02 |
| Stage3-vs-Stage4 |
4.392600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
7.91619999995774E-07 |
| Normal-vs-Asian |
1.80329995380646E-09 |
| Caucasian-vs-AfricanAmerican |
9.446200E-01 |
| Caucasian-vs-Asian |
8.727000E-01 |
| AfricanAmerican-vs-Asian |
9.653000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.23234755733392E-14 |
| Normal-vs-Female |
1.62436730732907E-12 |
| Male-vs-Female |
9.292600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.63846713974181E-12 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
1.63713487211226E-12 |
| Normal-vs-Age(81-100Yrs) |
2.201800E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.860400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.956400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.767200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.307800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.849200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.662800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.824200E-04 |
| Classical-VS-Follicular |
8.690100E-02 |
| Classical-VS-Other |
1.751840E-01 |
| Classical-VS-Normal |
1.55250035049903E-10 |
| Tall-VS-Follicular |
1.668430E-01 |
| Tall-VS-Other |
9.644000E-01 |
| Tall-VS-Normal |
1.32671651442706E-13 |
| Follicular-VS-Other |
5.521400E-01 |
| Follicular-VS-Normal |
3.4493519152079E-12 |
| Other-VS-Normal |
2.029400E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
6.66133814775094E-16 |
| Normal-vs-N1 |
1.76947345664757E-12 |
| N0-vs-N1 |
1.155850E-01 |
|
|
